Table 2.
Demographic and baseline characteristics (all enrolled analysis set)
| Parameters | Bortezomib |
|---|---|
| N = 517 | |
| Male, n (%) | 300 (58.0) |
| Age, years | 488; 58.7 (31.3–82.5) |
| Weight, kg, n; mean (SD) | 512; 64.0 (10.8) |
| Myeloma type, n (%) | |
| Immunoglobulin G | 239 (46.2) |
| Immunoglobulin A | 124 (24.0) |
| Light chain | 98 (19.0) |
| Non-secretory | 20 (3.9) |
| Immunoglobulin D | 19 (3.7) |
| Immunoglobulin M | 5 (1.0) |
| Plasma cell leukemia | 4 (0.8) |
| Solitary plasmacytoma | 3 (0.6) |
| Smoldering | 1 (0.2) |
| Biclonal | 1 (0.2) |
| Missing | 3 (0.6) |
| Time from initial diagnosis to first dose, years, n; mean (SD) | 475; 2.0 (3.1) |
| Durie–Salmon staging at initial diagnosis, n (%) | |
| IIIa | 247 (47.8) |
| IIIb | 100 (19.3) |
| IIa | 76 (14.7) |
| Unclear | 50 (9.7) |
| I | 24 (4.6) |
| IIb | 18 (3.5) |
| Serum beta-2 microglobulin, mg/L | 368; 3.9 (0.9–39.9) |
| C reactive protein, mg/L | 252; 6.0 (0–189.6) |
| Hemoglobin, g/L | 500; 92.0 (11.0–175.0) |
| Platelet count, 109/L | 453; 163.0 (50.0–461.0) |
| Serum creatinine, mg/dL | 191; 1.4 (1.0–7.6) |
| WBC, 109/L | 493; 4.3 (1.2–28.4) |
Data presented as n; median (range), unless otherwise specified. All enrolled analysis set included patients who were enrolled in the study
SD standard deviation, WBC white blood cells